| Title |
Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
|
|---|---|
| Published in |
Hepatic medicine evidence and research, March 2016
|
| DOI | 10.2147/hmer.s62014 |
| Pubmed ID | |
| Authors |
Stanislas Pol, Marion Corouge, Anaïs Vallet-Pichard |
| Abstract |
The treatment of hepatitis C virus has changed dramatically with the rapid advent of numerous new antiviral agents, including direct-acting antivirals and agents with non-viral targets (cyclophilin inhibitors, interferon-lambda, vaccine therapy). Given the better safety profile and high antiviral potency of direct-acting antivirals, their combination in interferon-free oral regimens is becoming the standard of care for hepatitis C virus infection, tailored to individual patients according to the degree of disease progression (fibrosis), hepatitis C virus genotype and subtype, resistance profile, and prior therapeutic history. Results from clinical studies as well as preliminary real-life data regarding the combination of sofosbuvir (a nucleotide polymerase inhibitor) and daclatasvir, a first-in-class NS5A replication complex inhibitor, demonstrate that it is one of the most promising antiviral therapies, with once-daily oral dosing, a low pill burden, good tolerability, and limited drug-drug interactions, in addition to high antiviral potency, with >90% sustained virologic response rates. This combination has high pangenotypic antiviral potency regardless of the severity and patient characteristics. The combination of sofosbuvir and an NS5A inhibitor with ribavirin for 12 weeks appears to be a very good further treatment option in both cirrhotic and treatment-experienced patients whatever the stage of fibrosis. |
Mendeley readers
The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 93 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 15 | 16% |
| Student > Bachelor | 15 | 16% |
| Other | 7 | 8% |
| Student > Ph. D. Student | 7 | 8% |
| Student > Postgraduate | 6 | 6% |
| Other | 17 | 18% |
| Unknown | 26 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 24% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 11% |
| Biochemistry, Genetics and Molecular Biology | 9 | 10% |
| Agricultural and Biological Sciences | 6 | 6% |
| Immunology and Microbiology | 3 | 3% |
| Other | 14 | 15% |
| Unknown | 29 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2024.
All research outputs
#5,344,962
of 25,394,764 outputs
Outputs from Hepatic medicine evidence and research
#22
of 116 outputs
Outputs of similar age
#76,348
of 312,692 outputs
Outputs of similar age from Hepatic medicine evidence and research
#2
of 4 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 116 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,692 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.